Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 19/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 17/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311204 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6310094 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL6310068 | 0.99 | OPRD1 (0.97) | OPRD1OPRM1OPRK1 | |
| Fumaric Acid SCHEMBL6309226 | 0.94 | OPRD1 (0.89) | OPRD1OPRM1OPRK1 | |
| Fumaric Acid SCHEMBL6309238 | 0.94 | OPRD1 (0.89) | OPRD1OPRM1OPRK1 | |
| Fumaric Acid SCHEMBL7490201 | 0.94 | OPRD1 (0.89) | OPRD1OPRM1OPRK1 | |
| Fumaric Acid SCHEMBL6309233 | 0.94 | OPRD1 (0.89) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5681661 | 0.88 | OPRM1 (0.79) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6717020 | 0.85 | OPRM1 (0.74) | OPRD1OPRM1 | |
| SCHEMBL6316561 | 0.83 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004163-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
| US-20030181447-A1 | 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | BOYD ROBERT E (US) | 2003-09-25 | — | — | US | disclosed |
| US-6552036-B2 | Delta-opioid or mu-opioid receptor modulators; useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of respiratory diseases. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020115662-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | BOYD ROBERT E (US) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004163-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885OPRK1 3/4885 |
| US-20020115662-A1 | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
| US-20030181447-A1 | 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.